Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial

Y. Abu-Ghanem, J.V. van Thienen, C. Blank, Maureen J.B. Aarts, M. Jewett, I.J. de Jong, J.B. Lattouf, H.H.E. van Melick, L. Wood, P. Mulders, S. Rottey, J. Wagstaff, P. Zondervan, T. Powles, A. Neven, L. Collette, B. Tombal, J. Haanen, A. Bex*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Number of pages8
JournalBJU International
DOIs
Publication statusE-pub ahead of print - 24 Nov 2021

Keywords

  • cytoreductive nephrectomy
  • deferred
  • immediate
  • renal cell carcinoma
  • sunitinib
  • survival
  • #uroonc
  • #kcsm
  • #KidneyCancer
  • RENAL-CELL CARCINOMA
  • PLANNED NEPHRECTOMY
  • TARGETED THERAPY

Cite this